Minerva Neurosciences, INC. (NERV) SEC Filings — 2025

Filings

• Minerva Neurosciences, INC. 8-K Filing — 8-K · Dec 22, 2025
• Minerva Neurosciences Seeks to Double Authorized Shares, Boost Equity Plan — DEF 14A · Nov 24, 2025
• Minerva Neurosciences Reports Director/Officer Changes & Compensation — 8-K · Nov 19, 2025
• Minerva Swings to $9.76M Loss, Secures $80M for Roluperidone Trial — 10-Q · Nov 5, 2025
• Minerva Neurosciences Files 8-K with Key Corporate Updates — 8-K · Oct 22, 2025
• NERV's Losses Narrow Amid R&D Cuts, But Liquidity Concerns Mount — 10-Q · Aug 14, 2025
• Minerva Neurosciences Files Q1 2025 10-Q — 10-Q · May 13, 2025
• Minerva Neurosciences Files 2024 10-K Amendment — 10-K/A · Apr 29, 2025
• Minerva Neurosciences Files 2024 Annual Report Amendment — 10-K/A · Apr 21, 2025
• Minerva Neurosciences Files 8-K — 8-K · Mar 19, 2025
• Minerva Neurosciences Files 2024 10-K — 10-K · Feb 25, 2025
• Sosei to Acquire Minerva Neurosciences for $1.5B — 8-K · Jan 13, 2025